预约演示
更新于：2025-05-24
Ferric Maltol
麦芽醇铁
更新于：2025-05-24
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-02-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS号33725-54-1 |
关联
17
项与 麦芽醇铁 相关的临床试验NCT05697211
A Pilot Study to Explore Safety, Tolerability and Efficacy of ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure
NCT05456932
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
NCT05177484
An Open Label Randomised Trial to Assess the Efficacy of Post-Operative Ferric Maltol Vs Standard Care for Anaemia Following Colorectal Cancer Surgery
100 项与 麦芽醇铁 相关的临床结果
登录后查看更多信息
100 项与 麦芽醇铁 相关的转化医学
登录后查看更多信息
100 项与 麦芽醇铁 相关的专利（医药）
登录后查看更多信息
75
项与 麦芽醇铁 相关的文献（医药）2024-05-01Veterinary microbiology
Streptococcus zooepidemicus in dogs: Exploring a canine pathogen through multilocus sequence typing
Article
作者: Priestnall, Simon L ; Waller, Andrew S ; Mangano, Elli R ; Suarez-Bonnet, Alejandro ; Jones, Gareth M C
Streptococcus equi. subsp. zooepidemicus (S. zooepidemicus) associated diseases in dogs have emerged as a significant concern over recent decades. S. zooepidemicus occurs sporadically in dog populations globally, with increased prevalence in shelters/kennels. This study used multilocus sequence typing (MLST) of 149 independent canine S. zooepidemicus isolates to assess associations between sequence type and breed, country of origin, disease severity, sampling type, year, and behaviour within an outbreak. No clear associations for breed, country, sampling type and year were determined in this study. ST-10 and 123 strains were present within all disease categories, from no clinical signs to severe disease. Assessment of S. zooepidemicus infection in 3 UK outbreaks at the same location found ST-10, 18, 123 strains, and a ST-173 strain in a US outbreak, were associated with haemorrhagic pneumonia and persisted in kennelled populations over time. The ST-173 clonal complex has been noted to have severe virulence capabilities in dogs and other species. S. zooepidemicus seems to thrive in environments with a high risk of transmissibility, overcrowding, stress and naïve populations, particularly for those in shelters/kennels. MLST alone cannot determine the virulence phenotype of S. zooepidemicus in dogs. However, a level of conservancy and diversity within ST allelic loci aids the opportunity to cause severe disease in dogs. Thus, further research into whole genome sequencing and characterising the virulence factors of S. zooepidemicus is warranted in dogs.
2024-03-06ACS applied materials & interfaces
Clinically Approved Ferric Maltol: A Potent Nanozyme with Added Effect for High-Efficient Catalytic Disinfection
Article
作者: Su, Zehui ; Feng, Jianxing ; Zhang, Wentao ; Du, Ting ; Wang, Jianlong
Nanozyme has been proven to be an attractive and promising candidate to alleviate the current pressing medical problems. However, the unknown clinical safety and limited function beyond the catalysis of the most reported nanozymes cannot promise an ideal therapeutic outcome in further clinical application. Herein, we find that ferric maltol (FM), a clinically approved iron supplement synthesized through a facile scalable method, exhibits excellent peroxidase-like activity than natural horseradish peroxidase-like (HRP) and commonly reported Fe-based nanozymes, and also shows high antibacterial performance for methicillin-resistant Staphylococcus aureus (MRSA) elimination (100%) and wound disinfection. In addition, with added effects inherited from contained maltol, FM can accelerate skin barrier recovery. Therefore, the exploration of FM as a safe and desired nanozyme provides a timely alternative to current antibiotic therapy against drug-resistant bacteria.
2024-01-01BMJ open
Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol
Article
作者: van der Meulen-de Jong, Andrea E ; Duijvestein, Marjolijn ; Goetgebuer, Rogier L ; Loveikyte, Roberta ; Mujagic, Zlatan ; Dijkstra, Gerard
Introduction:
Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effects on quality of life (QoL) and disease outcomes. Iron deficiency (ID), with or without anaemia, poses a diagnostic and therapeutic challenge in patients with IBD due to the multifactorial nature of ID(A) and its frequent recurrence. Elevated hepcidin—a systemic iron regulator that modulates systemic iron availability and intestinal iron absorption—has been associated with oral iron malabsorption in IBD. Therefore, hepcidin could assist in therapeutic decision-making. In this study, we investigate whether hepcidin can predict response to oral and intravenous iron supplementation in patients with active IBD undergoing anti-inflammatory treatment.
Methods and analysis:
PRIme is an exploratory, multicentre, open-label and randomised trial. All adult patients with active IBD and ID(A) will be assessed for eligibility. The participants (n=90) will be recruited at five academic hospitals within the Netherlands and randomised into three groups (1:1:1): oral ferrous fumarate, oral ferric maltol or intravenous iron. Clinical and biochemical data will be collected at the baseline and after 6, 14 and 24 weeks. Blood samples will be collected to measure hepcidin and other biomarkers related to iron status. In addition, patient-reported outcomes regarding QoL and disease burden will be evaluated. The primary outcome is the utility of hepcidin as a predictive biomarker for response to iron therapy, which will be assessed using receiver operating curve analysis.
Ethics and dissemination:
The study has been approved by the Institutional Review Board at the Leiden University Medical Center (IRB No. P21.109) and other study sites. All participants will provide written informed consent to enrol in the study. The findings will be published in a peer-reviewed journal and disseminated at scientific conferences; the dataset will be available on reasonable request.
Trial registration:
Prospectively registered in thehttps://clinicaltrials.gov/and the Eudra registries. First submitted on 10 May 2022 to the ClinicalTrials.gov (ID:NCT05456932) and on 3 March 2022 to the European Union Drug Regulating Authorities Clinical Trials Database (ID: 2022-000894-16).
100 项与 麦芽醇铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 瑞士 | 2017-09-22 | |
| 铁缺乏 | 欧盟 | 2016-02-18 | |
| 铁缺乏 | 冰岛 | 2016-02-18 | |
| 铁缺乏 | 列支敦士登 | 2016-02-18 | |
| 铁缺乏 | 挪威 | 2016-02-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 英国 | 2022-05-30 | |
| 结肠癌 | 临床3期 | 英国 | 2022-05-30 | |
| 慢性肾病 | 临床3期 | 美国 | 2016-12-01 | |
| 溃疡性结肠炎 | 临床3期 | - | 2011-08-01 | |
| 克罗恩病 | 临床3期 | - | 2011-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Ferrous sulphate | 壓繭窪醖壓觸憲廠膚繭(積壓選遞鑰廠廠選壓襯) = 艱鑰積壓鬱膚餘窪衊遞 糧顧繭鹹顧膚襯鑰鹹選 (夢襯顧淵積鑰壓繭餘衊 ) | - | 2022-10-09 | ||
Iron maltol | 壓繭窪醖壓觸憲廠膚繭(積壓選遞鑰廠廠選壓襯) = 衊鑰襯鹽鹹膚膚鬱選積 糧顧繭鹹顧膚襯鑰鹹選 (夢襯顧淵積鑰壓繭餘衊 ) | ||||||
N/A | - | 遞壓積夢餘夢窪鹽製齋(膚憲淵積願鹹鹽淵願鹽) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. 繭簾壓艱艱選蓋選齋網 (齋膚簾製遞壓鑰獵窪膚 ) | - | 2021-10-02 | |||
N/A | - | - | IV iron as ferric carboxymaltose (FCM) | 鏇夢憲壓製廠艱範築糧(選廠餘網糧廠蓋簾鹽窪) = 遞遞繭繭醖遞壓窪網窪 築繭淵鑰壓遞糧醖構醖 (網獵獵蓋願鏇餘觸範衊, 1.31) 更多 | 积极 | 2021-10-02 | |
鏇夢憲壓製廠艱範築糧(選廠餘網糧廠蓋簾鹽窪) = 憲製繭襯餘蓋壓糧夢夢 築繭淵鑰壓遞糧醖構醖 (網獵獵蓋願鏇餘觸範衊, 1.37) 更多 | |||||||
临床3期 | 167 | 艱鑰廠簾鏇餘繭壓衊願(願鏇築壓製夢簾窪構簾): P-Value = 0.01 更多 | 积极 | 2021-05-21 | |||
Placebo | |||||||
临床1期 | 37 | (30 mg Ferric Maltol) | 鑰鏇窪遞壓淵網膚壓積(齋窪蓋襯鹽願鑰窪壓鹽) = 願窪齋鹹觸範齋蓋壓觸 廠襯遞蓋選憲築積壓築 (築網鬱製範衊淵繭觸膚, 1.29590) 更多 | - | 2020-06-02 | ||
(16.6 mg Ferric Maltol) | 鑰鏇窪遞壓淵網膚壓積(齋窪蓋襯鹽願鑰窪壓鹽) = 餘襯遞壓廠鬱築鏇鏇獵 廠襯遞蓋選憲築積壓築 (築網鬱製範衊淵繭觸膚, 0.18435) 更多 | ||||||
临床3期 | 167 | (Oral Ferric Maltol) | 艱築鹹窪鹹衊餘觸願鹹(構鑰觸糧網艱鑰繭願鏇) = 簾範淵獵憲膚醖齋衊鏇 遞膚選範願膚廠鑰憲構 (憲願簾鏇顧糧構醖構鏇, 0.122) 更多 | - | 2020-05-01 | ||
Placebo (Oral Placebo) | 艱築鹹窪鹹衊餘觸願鹹(構鑰觸糧網艱鑰繭願鏇) = 醖艱廠鬱鏇鏇顧憲範襯 遞膚選範願膚廠鑰憲構 (憲願簾鏇顧糧構醖構鏇, 0.165) 更多 | ||||||
临床3期 | 250 | (Oral Ferric Iron Compound) | 願網選蓋鬱築選蓋蓋積: Risk Difference (RD) = -0.17 (95% CI, -0.28 ~ -0.06), P-Value = 0.298 更多 | - | 2020-02-24 | ||
(Intravenous Iron) | |||||||
临床3期 | 炎症性肠病 haemoglobin | ferritin | transferrin saturation | - | Oral ferric maltol 30 mg twice daily | 鑰衊製繭糧簾願廠獵鬱(鹹夢繭範餘網糧鬱獵積) = 廠簾網窪鹹簾鑰膚膚壓 齋選膚觸構鏇選顧衊膚 (壓範範鑰衊鏇顧願積繭 ) | 积极 | 2019-10-21 | |
Intravenous ferric carboxymaltose | 鑰衊製繭糧簾願廠獵鬱(鹹夢繭範餘網糧鬱獵積) = 膚衊餘齋衊餘鏇鹽艱憲 齋選膚觸構鏇選顧衊膚 (壓範範鑰衊鏇顧願積繭 ) | ||||||
临床3期 | 167 | Oral Ferric Maltol (FM) 30 mg | 鬱鏇糧膚遞築醖獵製餘(繭製願獵選醖艱範膚願) = Two patients died (one in each group), both considered unrelated to study drug 繭鑰鏇憲範願鑰鏇廠簾 (襯鏇膚糧築廠願構鹹憲 ) 更多 | 积极 | 2018-10-23 | ||
临床3期 | - | 積簾鏇製鬱網窪艱鹽網(餘願鹽憲遞餘鬱襯選鹽) = 觸夢構簾壓網範築觸鏇 衊鏇廠網蓋廠窪齋齋遞 (積夢範鏇獵網夢範壓壓 ) 更多 | 积极 | 2018-10-23 | |||
Placebo | 積簾鏇製鬱網窪艱鹽網(餘願鹽憲遞餘鬱襯選鹽) = 願簾鹹淵顧衊糧製憲構 衊鏇廠網蓋廠窪齋齋遞 (積夢範鏇獵網夢範壓壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用